Alphatec (ATEC) Q2 2026 earnings review
Operating Leverage Shines as Surgical Engine Compounds
After a choppy Q1 characterized by an EOS capital equipment shortfall, Alphatec delivered a resurgent Q2 that firmly reestablished its profitability narrative. Total revenue stabilized at 15% YoY growth ($214M), but the real story is on the bottom line. Adjusted EBITDA margin reversed its Q1 dip, exploding to a record 16.8% ($36M) and driving a $11M non-GAAP net income. Management responded by raising full-year EBITDA guidance to $140M while reaffirming the top-line outlook. The core surgical machine continues to capture market share at an aggressive clip, though declining revenue per case indicates changing product mix headwinds.
🐂 Bull Case
Net new surgeon users accelerated to 24% YoY growth (up from 23% in Q1). This continues to be the leading indicator of ATEC's market share capture and future procedural volume.
Operating leverage is proving structural. A 420 bps YoY expansion in EBITDA margin and back-to-back trailing twelve-month positive free cash flow prove the company can self-fund its rapid growth.
🐻 Bear Case
Surgical case volumes grew 20%, but surgical revenue only grew 17%. This implies continued pressure on average revenue per case, likely driven by the same mix shifts (cervical, international, lower biologics attach rates) seen in Q1.
Despite achieving $11M in Non-GAAP net income, GAAP net loss remains heavily negative at $25.8M, weighed down by high stock-based compensation ($18.1M) and non-cash interest.
⚖️ Verdict: 🟢
Bullish. The Q2 print alleviates Q1's growth concerns. The 15% revenue growth is sustainable given the massive 24% influx of new surgeons, and the EBITDA guidance raise proves management's 'convoy effect' model naturally generates operating leverage.
Key Themes
The Procedural Ecosystem and 'Convoy Effect'
ATEC’s core strategy of selling entire procedural solutions (like PTP) rather than standalone widgets continues to drive aggressive market capture. This 'convoy effect' drew in a massive 24% YoY increase in net new surgeon users in Q2, which translated directly into 20% surgical case volume growth.
Material Inflection in Operating Leverage
The company has clearly crossed a profitability threshold. Non-GAAP operating expenses improved dramatically, yielding an Adjusted EBITDA margin of 16.8% (up 420 bps YoY). Management’s decision to raise the full-year EBITDA guide from $134M to $140M indicates that earlier infrastructure investments are now powerfully scaling against incremental revenue.
Persistent Revenue Per Case Dilution
A concerning disconnect remains between volume and revenue. In Q2, surgical case volume grew 20%, but surgical revenue only grew 17%. This ~300 bps gap implies a continued drop in average revenue per procedure. In prior quarters, management blamed a mix shift toward lower-ASP cervical cases, strong international growth (which dilutes ASP), and sluggish biologics attachment. If this mix shift is structural, it will force ATEC to rely increasingly on sheer volume to hit top-line targets.
EOS Capital Lumps Remain a Drag
While total revenue met expectations, the implied EOS revenue for Q2 is approximately $18M (Total $214M - Surgical $196M). While slightly better than Q1's $14M miss, the company previously had to slash its full-year EOS guidance to $77M due to hospital construction and installation volatility. EOS remains the linchpin for ATEC's data 'moat,' but its capital-sales nature introduces unpredictability into an otherwise highly recurring surgical revenue model.
Maturing Capital Structure Enhances Cash Flow
The Q2 results show the early benefits of the recent debt refinancing (Term Loan A maturing in 2031). Cash interest expense was $4.4M in Q2, down from $5.3M in the prior year period. By lowering borrowing costs by SOFR + 275 bps, the company is protecting its newly established positive free cash flow generation.
Other KPIs
Stable. Grew 17% YoY, exactly matching the 17% growth reported in Q1. While significantly decelerated from the ~30% rates seen in mid-2025, 17% represents a highly sustainable growth floor driven by massive new surgeon adoption.
Reversing. After burning $11M in Q1 primarily due to inventory and instrument investments, ATEC returned to positive FCF in Q2. Management maintained its full-year guidance of at least $20M.
Stable. The GAAP loss continues to be heavily distorted by non-cash charges. Q2 included $18.1M in stock-based compensation, $15.1M in depreciation, and $11.8M in loss on debt extinguishment from the recent refinancing.
Guidance
Accelerating. Raised from the prior $134M estimate. Implies a full-year margin of ~15.9%, demonstrating management's high confidence in continued operating expense leverage during the second half of the year.
Stable. Reaffirmed. Represents ~15% YoY growth. This implies a required run rate of roughly $238M per quarter for the back half of the year to meet the target, which aligns with historical seasonality bumps from deformity season.
Stable. Reaffirmed. Represents ~17% YoY growth. With H1 surgical revenue totaling $374M, the company needs $431M in H2, requiring roughly 16-17% YoY growth in the back half—a highly achievable setup given current momentum.
Stable. Reaffirmed. Confirms the company has fully transitioned out of its cash-burning infrastructure-build phase and into self-funded, profitable growth.
Key Questions
Drivers of Revenue Per Case Compression
Surgical case volumes grew 20% but surgical revenue only grew 17%. Is this 300 bps gap purely a mix shift toward cervical/OUS, or are you seeing defensive pricing actions from competitors attempting to retain share?
Biologics Attachment Update
In Q1, you noted that sluggish biologics attachment (38%) was a headwind and expected it to improve during the Q2 deformity season. Did biologics attachment meet internal expectations this quarter?
Capital Expenditure Requirements for New Surgeons
With net new surgeon users accelerating to 24% growth, how are you managing the heavy upfront instrument and set investments without jeopardizing your $20M free cash flow target for the year?
EOS Execution Rebound
After the Q1 shortfall due to 'lumpy' hospital construction timelines, how did EOS capital placements track against your revised internal plans for Q2? Are hospital capital environments delaying structural build-outs?